3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
16
Recruiting
8
Unknown
2
Terminated
2
Not yet recruiting
2
Enrolling by invitation
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboprophylaxis
1
Pulmonary Embolism
1
Neoplasms
1
Interventions
Cisplatin
122
Carboplatin
120
Drug Therapy
104
Bevacizumab
101
Capecitabine
96
Oxaliplatin
95
Radiotherapy
92
Gemcitabine
88
Paclitaxel
87
tislelizumab
84
Cyclophosphamide
83
Specimen Handling
80
pembrolizumab
76
toripalimab
66
Magnetic Resonance Spectroscopy
63
Fluorouracil
61
sintilimab
58
Injections
57
anlotinib
51
Docetaxel
51
Surgical Procedures, Operative
48
130-nm albumin-bound paclitaxel
48
fludarabine
45
Pemetrexed
43
Standard of Care
42
Biopsy
42
venetoclax
41
Irinotecan
41
lenvatinib
40
Leucovorin
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Interventional
×
apixaban
×
Clear all
NCT07493304
2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Not yet recruiting
1,600 enrolled
NCT07160686
2025-09-08
THROMBO-STOP
University of Birmingham
Phase 3
Not yet recruiting
1,456 enrolled